Search company, investor...
Cristal Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Grant - II | Alive

Total Raised


Last Raised

$3M | 5 yrs ago

Mosaic Score

+30 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Cristal Therapeutics

Cristal Therapeutics, established in Maastricht, focuses on the development of nanomedicines with improved therapeutic efficacy. The pipeline comprises of products based on drugs in development and also on the market, in combination with the patented CriPec platform, for the treatment of various diseases, including cancer and chronic inflammatory disorders. CriPec transforms drugs into polymer nanoparticles via an innovative process. These nanoparticles provide improved distribution throughout the body. The substantial improvement of the efficacy and safety of the drugs entrapped in CriPec nanoparticles has already been demonstrated in animal studies. Cristal Therapeutics has demonstrated the benefits of CriPec for various molecules, including peptide drugs (an anticancer drug transported by a protein that is important for the tumour), as well as for applications such as active targeting for more selective treatment. The results to date have contributed to the company's present innovative product portfolio.

Cristal Therapeutics Headquarters Location

Oxfordlaan 55

Maastricht, 6229 EV,


+31 433 88 58 68

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cristal Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cristal Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Cristal Therapeutics News

New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non-Invasive Imaging

May 5, 2022

Search jobs 04-May-2022 New Data Opens Potential for Patient Stratification for CriPec® Nanomedicines in Cancer and Other Indications via Non-Invasive Imaging Maastricht, The Netherlands, 4 May 2022 – Cristal Therapeutics, a Dutch pharmaceutical company developing tailored nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the publication of the results of the clinical PICCOLO study in the peer-reviewed journal, Advanced Materials1. This first-of-its-kind study2, part funded by an EU Horizon 2020 and a Health Holland grant, applied radiolabelling and PET-imaging to non-invasively track CriPec® nanomedicines in patients with solid tumours over time. The data showed that a diagnostic dose of CriPec® nanomedicine radiolabelled with zirconium-89 (89Zr-CPC634) was reliably predictive for the behaviour of a therapeutic dose and provides a powerful tool to non-invasively monitor the biological journey, including tumour uptake. This opens up the potential of using this approach to stratify patients without exposing them to therapeutic dose levels and thus possible side effects. In the study, undertaken in close collaboration with researchers from Amsterdam University Medical Centre (location VUmc), radiolabelled CriPec® was followed by positron emission tomography / computed tomography (PET/CT) imaging in seven patients with solid tumours. A therapeutic dose as well as a diagnostic dose were administered, and pharmacokinetics and tumour uptake were assessed for both. Extended blood residence and substantial tumour uptake were observed and were in fact found to be comparable for both dose levels. These findings are significant as they provide further evidence for the long circulation and substantial tumour uptake of CriPec® nanomedicines in patients, as was previously observed in other clinical studies2,3. They further support the potential for superior therapeutic performance of CriPec® nanomedicines. In addition, the ability to monitor CriPec® nanoparticles in patients also provides Cristal Therapeutics with detailed information for use in its rational design process to engineer CriPec® nanomedicines for superior therapeutic performance and to stratify patients for precision medicine-based approaches. Dr Cristianne Rijcken, PharmD PhD, founder and CSO of Cristal Therapeutics said: “Despite the many advances in the nanomedicine field, the heterogeneity of tumours, both inter- and intra-patient, remains a major challenge. The non-invasive, diagnostic approach validated in this unique study provides valuable insight into the behaviour of CriPec® nanomedicines and gives Cristal Therapeutics a powerful tool to further enhance the rational design of our nanomedicines with the goal of stratifying patients for safer, more targeted anticancer treatments in the future.” Cristal Therapeutics is progressing a robust pipeline of nanoparticle therapeutic candidates which are rationally designed to target specific tissues, cells and intracellular components throughout the body. Its strategy is to partner its technology platforms and CriPec® based therapeutic products to maximise the potential for advancing new medicines in areas of high unmet need. Representatives from Cristal Therapeutics will be attending the BIO International Convention in San Diego 13-16 June 2022 – please contact . - ENDS - About the PICCOLO study In the PICCOLO clinical study, a docetaxel-entrapping polymeric nanoparticle was radiolabelled with zirconium-89 (89Zr-CPC634) and positron emission tomography / computed tomography (PET/CT) imaging was performed in seven patients with solid tumours of various origins with two different doses of CPC634: an on-treatment (containing 60 mg m-2 docetaxel) and a diagnostic (1-2 mg docetaxel) dose (NCT03712423). Pharmacokinetic half-life for 89Zr-CPC634 was mean 97.0 ±14.4 hours on-treatment, and 62.4 ±12.9 hours for the diagnostic dose (p = 0.003). At these doses accumulation was observed in 46% and 41% of tumour lesions with a median accumulation in positive lesions 96 hours post-injection of 4.94 and 4.45%IA kg-1 (p = 0.91), respectively. About Cristal Therapeutics Cristal Therapeutics applies three distinct and interconnected technologies together with biologic insights to improve the therapeutic profile of our partners’ programs in development. Based on over 10 years of real-world experience, the Company’s CliCr®, CriPec® and CriVac® technologies provide superior conjugation, enhance target specificity and engender highly selective immune responses, thereby increasing efficacy and reducing toxicity. Cristal Therapeutics aims to be the partner of choice for overcoming challenges and enabling the full potential of nanomedicines, bio-conjugates and vaccines, among a broad range of therapeutic areas, tuned to modality and indication. Find out more: References

Cristal Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cristal Therapeutics Rank

  • Where is Cristal Therapeutics's headquarters?

    Cristal Therapeutics's headquarters is located at Oxfordlaan 55, Maastricht.

  • What is Cristal Therapeutics's latest funding round?

    Cristal Therapeutics's latest funding round is Grant - II.

  • How much did Cristal Therapeutics raise?

    Cristal Therapeutics raised a total of $24.08M.

  • Who are the investors of Cristal Therapeutics?

    Investors of Cristal Therapeutics include Horizon 2020, BioGeneration Ventures, Utrecht Holdings, Brightlands Venture Partners, LIOF and 11 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.